Red blood cell alloimmunisation after platelet transfusion (excluding ABO blood group system).


Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 17 03 2020
revised: 26 05 2020
accepted: 08 06 2020
pubmed: 17 6 2020
medline: 30 7 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

Red blood cell alloimmunisation after transfusion of red blood cell concentrates carries a risk for every recipient. This risk is particularly high for patients with conditions such as sickle cell disease. However, red blood cell alloimmunisation can also occur after platelet concentrate transfusion. All blood group systems other than ABO are affected, and there are several mechanisms responsible for this alloimmunisation. The practical implications of this are a need to match red blood cell concentrates in all alloimmunised patients and, in pregnant women, recongnition of the risk of developing haemolytic disease of the foetus and newborn. Several measures can be taken to prevent alloimmunisation: in the case of the D antigen, for example, anti-RhD immunoglobulins can be infused before transfusing platelet concentrates from an RhD-positive donor in a RhD-negative recipient.

Identifiants

pubmed: 32544526
pii: S1246-7820(20)30072-0
doi: 10.1016/j.tracli.2020.06.001
pii:
doi:

Substances chimiques

Antigens, Surface 0
Blood Group Antigens 0
Isoantibodies 0
RHO(D) antibody 0
Rh-Hr Blood-Group System 0
Rho(D) Immune Globulin 0
Rho(D) antigen 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-190

Informations de copyright

Copyright © 2020 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

P Moncharmont (P)

Département des vigilances, hémovigilance, Établissement français du Sang Auvergne Rhône-Alpes, site de Lyon-Décines, 111, rue Elisée Reclus CS 20617, 69153 Décines-Charpieu cedex, France. Electronic address: pierre.moncharmont@efs.sante.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH